BioVie (BIVI) AI Stock Analysis

• Market Cap: $14.39M
• Dividend Yield: N/A
• Average Volume (3M): 251.11K
• Price to Earnings (P/E): ―
• Beta (1Y): 2.09
• Revenue Growth: N/A
• EPS Growth: 66.72%
• Country: US
• Employees: 14
• Sector: Healthcare
• Sector Strength: 69
• Industry: Biotechnology
• EPS (TTM): -3.95
• Shares Outstanding: 18,451,980
• 10 Day Avg. Volume: 280,072
• 30 Day Avg. Volume: 251,114
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• Price to Cash Flow (P/CF): -0.60
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $6.00
• Price Target Upside: 669.23% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

BioVie is in the early stages of development, with no revenue and dependence on equity financing, reflected in poor financial performance. The bearish technical indicators further lower the stock's score. The company's valuation presents a high risk but possibly high reward scenario, common for biotech firms awaiting successful R&D outcomes.

BioVie Business Overview & Revenue Model

Company Description

BioVie Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of drugs therapies in the United States. Its products in pipeline include BIV201, which completed Phase IIa clinical trial for the treatment of ascites due to chronic liver cirrhosis; and NE3107, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease and Phase I clinical trial for the treatment of Parkinson's disease. The company is also developing NE3107, which is in pre-clinical stage for the treatment of multiple myeloma and prostate cancer. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is based in Carson City, Nevada.

How the Company Makes Money

BioVie primarily makes money through the development and eventual commercialization of its pharmaceutical products. The company seeks to generate revenue by advancing its drug candidates through clinical trials, obtaining regulatory approvals, and partnering with larger pharmaceutical companies for distribution and marketing. Significant partnerships with research institutions and pharmaceutical firms play a crucial role in funding research and development efforts. Additionally, BioVie may earn revenue through milestone payments and royalties as its products move closer to market availability and achieve commercial success.

BioVie Financial Statement Overview

Summary

BioVie is in the pre-commercialization phase, with no revenue and high reliance on equity financing. While the balance sheet shows a strong equity position, the company faces high net losses and a significant cash burn rate due to R&D activities.

Income Statement

BioVie shows consistent negative gross profit and net income, with no revenue generation, which is typical for early-stage biotech companies. The ongoing net losses and negative EBIT and EBITDA margins indicate a company still in the R&D phase without product commercialization. Growth metrics are not applicable due to zero revenue.

Balance Sheet

The balance sheet reflects a relatively high stockholders' equity and minimal debt, leading to a favorable debt-to-equity ratio. However, the company's equity ratio suggests reliance on equity financing, typical for biotech firms. The improving equity position is a positive sign, but the lack of tangible assets remains a concern.

Cash Flow

BioVie has negative operating and free cash flows, indicative of high cash burn in R&D activities. There is significant reliance on financing cash flows to maintain operations. The lack of positive cash flow metrics highlights the company's current inability to generate cash from operations.

Breakdown
TTM	Jun 2024	Jun 2023	Jun 2022	Jun 2021	Jun 2020
Income Statement		Total Revenue
0.00	0.00	0.00	0.00	0.00	0.00
	Gross Profit
-229.38K	-229.38K	-266.84K	-237.42K	-229.38K	-229.38K
	EBIT
-23.94M	-32.18M	-45.08M	-27.25M	-138.05M	-2.69M
	EBITDA
-22.96M	-31.95M	-45.69M	-23.68M	-137.80M	-2.46M
	Net Income Common Stockholders
-25.20M	-32.12M	-50.26M	-26.08M	-183.85M	-33.78M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
45.75M	23.84M	33.94M	18.64M	4.51M	37.20K
	Total Assets
47.19M	25.21M	35.10M	20.11M	6.05M	2.08M
	Total Debt
13.37M	6.11M	14.42M	12.26M	0.00	911.04K
	Net Debt
-32.38M	-17.73M	-5.04M	-6.38M	-4.51M	873.85K
	Total Liabilities
21.12M	9.70M	19.76M	16.44M	996.37K	23.58M
	Stockholders Equity
26.07M	15.51M	15.34M	3.67M	5.05M	-21.50M
Cash Flow		Free Cash Flow
-22.02M	-27.95M	-40.25M	-18.99M	-10.45M	-1.63M
	Operating Cash Flow
-22.02M	-27.95M	-40.25M	-18.99M	-10.45M	-1.63M
	Investing Cash Flow
0.00	14.53M	-14.30M	0.00	0.00	0.00
	Financing Cash Flow
26.20M	17.80M	55.37M	33.12M	14.93M	1.33M

BioVie Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.78
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BIVI, the sentiment is Negative. The current price of 0.78 is below the 20-day moving average (MA) of 0.96, below the 50-day MA of 1.28, and below the 200-day MA of 2.37, indicating a bearish trend. The MACD of -0.14 indicates Negative momentum. The RSI at 28.65 is Positive, neither overbought nor oversold. The STOCH value of 11.06 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BIVI.

BioVie Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ACAD	76 Outperform	$2.43B	10.72	38.89%	―	31.85%	―
AVXL	62 Neutral	$753.67M	―	-37.72%	―	―	-3.08%
AXSM	51 Neutral	$4.78B	―	-231.63%	―	42.53%	-15.29%
INMB	49 Neutral	$169.23M	―	-119.83%	―	-90.97%	-27.47%
Sector *	48 Neutral	$6.35B	1.19	-46.26%	2.67%	19.24%	1.75%
SAVA	42 Neutral	$61.35M	―	-17.19%	―	―	81.00%
BIVI	36 Underperform	$14.39M	―	-154.54%	―	―	66.72%

BioVie Corporate Events

BioVie Raises $3.24 Million in Direct Offering

BioVie Inc. announced the successful closing of its registered direct offering, raising $3.24 million by selling 1,146,000 shares of its common stock at $2.83 per share. The funds will primarily be used for working capital and corporate purposes. As a clinical-stage company, BioVie is developing innovative therapies for chronic conditions like liver disease and neurodegenerative disorders, with promising drug candidates in the pipeline.

BioVie Raises Capital Through Direct Stock Offering

BioVie Inc. has launched a registered direct offering, selling 1,146,000 shares of its common stock at $2.83 per share, aiming to raise approximately $3.2 million. The proceeds will be used primarily for working capital and general corporate purposes. The offering, managed by ThinkEquity, is set to close on October 29, 2024, and is made under a shelf registration statement filed with the SEC.

BioVie Raises $6 Million in Strategic Funding

BioVie Inc., a clinical-stage company developing treatments for chronic conditions, has successfully closed a direct offering and private placement, raising approximately $6 million. The funds will be primarily used for working capital and general corporate purposes. This strategic financial move reflects BioVie’s ongoing commitment to advancing its innovative drug therapies, including those for neurodegenerative disorders and liver disease, amidst market uncertainties and potential risks.

BioVie Announces $6 Million Stock Offering and Placement

BioVie Inc., a clinical-stage company, has announced a registered direct offering and concurrent private placement, pricing 2,667,000 shares of its common stock at $2.25 per share, with unregistered warrants allowing purchase of additional shares at $2.12 each. This deal, facilitated by ThinkEquity, aims to raise approximately $6 million before expenses, with proceeds earmarked for working capital and corporate purposes. The offering is set to close around October 24, 2024, pending customary conditions.

BioVie Secures $6.66 Million Through Direct Offering

BioVie Inc. has announced the successful closing of a registered direct offering and concurrent private placement, raising gross proceeds of approximately $6.66 million. The offering included 4,443,000 shares of common stock at $1.50 per share and warrants for the same number of shares at an exercise price of $1.37 per share. The company plans to use the funds for working capital and corporate purposes. This development is significant for investors tracking BioVie’s financial maneuvers and potential growth in the biopharmaceutical sector.

BioVie Announces Stock Offering and Private Placement

BioVie Inc. announced a direct stock offering and a private placement, aiming to raise approximately $6.66 million through the sale of shares at $1.50 each. Additionally, the company will issue warrants exercisable for shares at $1.37 per share. These funds are intended for working capital and corporate purposes, with the offering closing expected on October 22, 2024. The company is focused on developing treatments for liver and neurological diseases.